Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model

Zeitschrift fur Kardiologie

Volumn 94, Issue 7, 2005, Pages 445-452

  Scheller, B ^a   Grandt, A ^b   Wnendt, S ^c   Lorenz, G ^b   Bohm M ^a   Nickenig, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c Kourion Therapeutics AG   (Germany)

Author keywords

Drug eluting stent; Paclitaxel; Restenosis; Tacrolimus

Indexed keywords

PACLITAXEL; POLYMER; TACROLIMUS;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEATH; DOMESTIC ANIMAL; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; FOLLOW UP; IN-STENT RESTENOSIS; MINIPIG; MORPHOMETRICS; NONHUMAN;

ANIMALS; BLOOD VESSEL PROSTHESIS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; SWINE; SWINE, MINIATURE; TACROLIMUS; TREATMENT OUTCOME;

EID: 21844467014     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-005-0237-y     Document Type: Article

References (26)

1. Suzuki T, Kopia G, Hayashi S, et al (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193
2. Morice MC, Serruys PW, Sousa JE, et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
3. Moses JW, Leon MB, Popma JJ, et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
4. Heldman AW, Cheng L, Jenkins GM, et al (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289-2295
5. Grube E, Silber S, Hauptmann KE, et al (2003) TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42
6. Stone GW, Ellis SG, Cox DA, et al (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231
7. Virmani R, Guagliumi G, Farb A, et al (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701-705
8. McFadden EP, Stabile E, Regar E, et al (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519-1521
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol) (1995) N Engl J Med; 332:1004-1014
10. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G (2003) Addition of Paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42:1415-1420
11. Zohlnhöfer D, Klein CA, Richter T, et al (2001) Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter Aatherectomy. Detection of FK506-binding protein 12 upregulation. Circulation 103:1396-1402
12. Griffith JP, Kim JL, Kim EE, et al (1995) X-ray structure of calcineurin inhibited by the immunophilin-immunosppressant FKBP12-FK506 complex. Cell 82:507-522
13. Matter MC, Wnendt S, Kurz DJ, et al (2002) Tacrolimus, but not sirolimus targets human vascular smooth muscle cells, but spares endothelial cells - Implications for drug-eluting stents. Eur Heart J 4 (Abstr. Suppl):143
14. Mohacsi PJ, Tüller D, Hulliger B, Wijngaard P (1997) Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16:484-492
15. Wieneke H, Dirsch O, Sawitowski T, et al (2003) Catheter Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cardiovasc Interv 60:399-407
16. Schwartz RS, Holmes DR, Topol EJ (1992) The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20:1284-1293
17. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB (1998) In-stent restenosis contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224-230
18. Colombo A, Drzewiecki J, Banning A, et al (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel eluting stents for coronary artery lesions. Circulation 108:788-794
19. Costa MA, Sabate M, van der Giessen WJ et al (1999) Late coronary occlusion after intracoronary brachytherapy. Circulation 100:789-792
20. Kozuma K, Costa MA, Sabate M, et al (1999) Late stent malapposition occurring after intracoronary beta-irradiation detected by intravascular ultrasound. J Invasive Cardiol 11:651-655
21. Albiero R, Nishida T, Adamian M, et al (2000) Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 101:2454-2457
22. van der Giessen WJ, Lincoff AM, Schwartz RS, et al (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94:1690-1697
23. Farb A, Heller PF, Shroff S, et al (2001) Pathological analysis of local delivery of paclitaxel via a polymercoated stent. Circulation 104:473-479
24. Carter AJ, Aggarwal M, Kopia GA, et al (2002) Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63:617-624
25. Poon M, Badimon JJ, Fuster V (2002) Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 359:619-622
26. Virmani R, Farb A, Kolodgie F (2002) Histopathologic alterations after endovascular radiation and anti-proliferative stents: similarities and differences. Herz 27:1-6